Proinflammatory effects and molecular mechanisms of interleukin-17 in intestinal epithelial cell line HT-29

World Journal of Gastroenterology

Volumn 20, Issue 47, 2014, Pages 17924-17931

  Wang, Yi Lin ^a,d   Fang, Meng ^b   Wang, Xiao Ming ^c   Liu, Wei Yan ^d   Zheng, Yun Jiang ^a   Wu, Xu Bo ^d   Tao, Ran ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Department of Anesthesia the 88Th Hospital of PLA ^*  (China)

^c WANNAN MEDICAL COLLEGE   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

HT 29; IL 17; Inflammatory bowel disease; Tnf

Indexed keywords

CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERLEUKIN 17; INTERLEUKIN 8; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE INHIBITOR; TRAF3IP2 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; INTESTINE EPITHELIUM CELL; MOLECULAR MECHANICS; NEUTROPHIL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TH17 CELL; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HT 29 CELL LINE; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; METABOLISM; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME;

EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HT29 CELLS; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-17; INTESTINAL MUCOSA; NEUTROPHILS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919774547     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i47.17924     Document Type: Article

References (30)

1. Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am 2014; 43: 603-617 [PMID: 25110261 DOI: 10.1016/j.gtc.2014.05.011]
2. Thia KT, Loftus EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008; 103: 3167-3182 [PMID: 19086963 DOI: 10.1111/j.1572-0241.2008.02158.x]
3. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474 : 307-317 [PMID: 21677747]
4. Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013; 62: 1505-1510 [PMID: 24037875 DOI: 10.1136/gutjnl-2012-303954]
5. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70 [PMID: 12477762 DOI: 10.1136/gut.52.1.65]
6. Hundorfean G, Neurath MF, Mudter J. Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 180-186 [PMID: 21381156 DOI: 10.1002/ibd.21677]
7. Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, Magorien JE, Blauvelt A, Kolls JK, Cheung AL, Cheng G, Modlin RL, Miller LS. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 2010; 120: 1762-1773 [PMID: 20364087 DOI: 10.1172/JCI40891]
8. Agache I, Ciobanu C, Agache C, Anghel M. Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med 2010; 104 : 1131-1137 [PMID: 20338742 DOI: 10.1016/ j.rmed.2010.02.018]
9. Wu Y, Zhu L, Liu L, Zhang J, Peng B. Interleukin-17A stimulates migration of periodontal ligament fibroblasts via p38 MAPK/NF-κB -dependent MMP-1 expression. J Cell Physiol 2014; 229: 292-299 [PMID: 23929359 DOI: 10.1002/jcp.24444]
10. Hering NA, Andres S, Fromm A, van Tol EA, Amasheh M, Mankertz J, Fromm M, Schulzke JD. Transforming growth factor-β, a whey protein component, strengthens the intestinal barrier by upregulating claudin-4 in HT-29/B6 cells. J Nutr 2011; 141: 783-789 [PMID: 21430244 DOI: 10.3945/ jn.110.137588]
11. Sergent JA, Paget V, Chevillard S. Toxicity and genotoxicity of nano-SiO2 on human epithelial intestinal HT-29 cell line. Ann Occup Hyg 2012; 56: 622-630 [PMID: 22378843 DOI: 10.1093/annhyg/mes005]
12. Roussel L, Houle F, Chan C, Yao Y, Bérubé J, Olivenstein R, Martin JG, Huot J, Hamid Q, Ferri L, Rousseau S. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 2010; 184: 4531-4537 [PMID: 20228195 DOI: 10.4049/jimmunol.0903162]
13. Fransen K, van Sommeren S, Westra HJ, Veenstra M, Lamberts LE, Modderman R, Dijkstra G, Fu J, Wijmenga C, Franke L, Weersma RK, van Diemen CC. Correlation of genetic risk and messenger RNA expression in a Th17/IL23 pathway analysis in inflammatory bowel disease. Inflamm Bowel Dis 2014; 20: 777-782 [PMID: 24662057 DOI: 10.1097/MIB.0000000000000013]
14. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ, Bruce AT. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011; 187: 490-500 [PMID: 21606249 DOI: 10.4049/jimmunol.1100123]
15. Weidlich S, Bulau AM, Schwerd T, Althans J, Kappler R, Koletzko S, Mayr D, Bufler P. Intestinal expression of the antiinflammatory interleukin-1 homologue IL-37 in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014; 59: e18-e26 [PMID: 24732025]
16. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013; 168: 402-411 [PMID: 23362969 DOI: 10.1111/bjd.12112]
17. Zhang Z, Hinrichs DJ, Lu H, Chen H, Zhong W, Kolls JK. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease? Int Immunopharmacol 2007; 7: 409-416 [PMID: 17321463]
18. Towne E, Maxwell J, Zhang Y. O037 Differential roles for IL-23 and IL-17 in inflammatory bowel disease. Cytokine 2012; 59: 515 [DOI: 10.1016/j.cyto.2012.06.074]
19. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767 [PMID: 21530742 DOI: 10.1053/j.gastro.2011.02.016]
20. Griffin GK, Newton G, Tarrio ML, Bu DX, Maganto-Garcia E, Azcutia V, Alcaide P, Grabie N, Luscinskas FW, Croce KJ, Lichtman AH. IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol 2012; 188: 6287-6299 [PMID: 22566565 DOI: 10.4049/jimmunol.1200385]
21. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, Nograles KE, Tian S, Cardinale I, Chimenti S, Krueger JG. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011; 131: 677-687 [PMID: 21085185 DOI: 10.1038/jid.2010.340]
22. Tanabe A, Konno J, Tanikawa K, Sahara H. Transcriptional machinery of TNF-α-inducible YTH domain containing 2 (YTHDC2) gene. Gene 2014; 535 : 24-32 [PMID: 24269672 DOI: 10.1016/j.gene.2013.11.005]
23. Lee HH, Yoon NA, Vo MT, Kim CW, Woo JM, Cha HJ, Cho YW, Lee BJ, Cho WJ, Park JW. Tristetraprolin down-regulates IL-17 through mRNA destabilization. FEBS Lett 2012; 586: 41-46 [PMID: 22138182 DOI: 10.1016/j.febslet.2011.11.021]
24. Li Q, Laumonnier Y, Syrovets T, Simmet T. Recruitment of CCR6-expressing Th17 cells by CCL20 secreted from plasminstimulated macrophages. Acta Biochim Biophys Sin (Shanghai) 2013; 45 : 593-600 [PMID: 23681234 DOI: 10.1093/abbs/gmt049]
25. Meares GP, Ma X, Qin H, Benveniste EN. Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Glia 2012; 60: 771-781 [PMID: 22319003 DOI: 10.1002/glia.22307]
26. Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K, Mizuguchi J, Itoh M, Kawakami Y, Yoshimoto T. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol 2013; 2013: 968549 [PMID: 23956763 DOI: 10.1155/2013/968549]
27. Chang SH, Park H, Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 2006; 281: 35603-35607 [PMID: 17035243 DOI: 10.1074/jbc.C600256200]
28. Kang Z, Wang C, Zepp J, Wu L, Sun K, Zhao J, Chandrasekharan U, DiCorleto PE, Trapp BD, Ransohoff RM, Li X. Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells. Nat Neurosci 2013; 16: 1401-1408 [PMID: 23995070 DOI: 10.1038/nn.3505]
29. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res 2012; 110: 159-173 [PMID: 22223212 DOI: 10.1161/CIRCRESAHA.111.243162]
30. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, Zanesi N, Crawford M, Ozer GH, Wernicke D, Alder H, Caligiuri MA, Nana-Sinkam P, Perrotti D, Croce CM. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA 2012; 109: E2110-E2116 [PMID: 22753494 DOI: 10.1073/pnas.1209414109]